| neratinib based treatment | tucatinib based treatment |
| neratinib | neratinib plus capecitabine | tucatinib plus trastuzumab plus capecitabine |
| la/mBC - HER2 positive - 2nd Line (L2) 13 | | | |
Comparator:
vs placebo; vs lapatinib plus capecitabine; vs trastuzumab plus capecitabine;
Risk of bias:
low;
some concerns;
high;
NA;